Wolters Kluwer Health today announced that it has acquired Medknow PVT Ltd., a leading Scientific, Technical & Medical (STM) journal publishing operation headquartered in Mumbai, India and one of the largest open access publishers in the world. The acquisition expands Wolters Kluwer Health's Medical Research business' presence in key developing markets and supports its strategy to increase locally written content and incorporate more open access platforms into its business model. Terms of the deal were not disclosed.
"Research is changing in the developing world with clinicians and researchers looking for more access to locally-written content that is peer-reviewed and accessible via open platforms," said Karen Abramson, President & CEO, Wolters Kluwer Health, Medical Research. "Our acquisition of Medknow aligns with our strategy of continuing to invest in providing the latest, most trusted information to our customers around the world to help them fuel discoveries and enhance patient care."
Founded in 1977, Medknow has a strong portfolio of more than 155 journals and offers much of its content electronically. The company has strong market share among journals published in India and also has a growing presence in Asia Pacific and the MEA region. In addition to its print and electronic journal content, the company provides an electronic peer-review system for authors and editors, ensuring high quality clinical research. The deal will enable Wolters Kluwer Health to accelerate advances in the open access arena. It also furthers the company's growth strategy of continued investment in international expansion in key emerging markets across the globe.
For Wolters Kluwer Health customers, the deal means expanded access to medical content in more markets around the world. Medknow's journals will join an extensive portfolio of nearly 300 practitioner journals, including those which are published by Wolters Kluwer Health's Lippincott Williams & Wilkins brand and additional journals made available through our society partnerships. There will also be opportunities via Wolters Kluwer Health's Ovid brand, which is the online source for the latest electronic research information used by the world's leading universities, academic research libraries, hospitals and pharmaceutical companies, among others.
New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis